Modern Management of Perianal Crohn’s Disease: A Review

2020 ◽  
pp. 000313482095633
Author(s):  
Jennifer L. Williams ◽  
Virginia O. Shaffer

Perianal Crohn’s disease (CD) is a complex manifestation of CD that affects approximately 10% of patients. The spectrum of disease is quite variable, ranging from relatively mild disease to severe, aggressive manifestations that result in frequent hospitalizations, multiple surgeries, and poor quality of life. Despite significant recent advances in surgical and medical management, treatment remains challenging and frequently requires a multidisciplinary medical-surgical approach. The goal of this article is to review the current literature regarding the work-up, treatment, and future directions of therapy. Crucial features of effective management include the precise identification of manifestations, control of sepsis, limiting rectal inflammation, frequently with use of antitumor necrosis factor agents, and avoidance of extensive surgery.

2020 ◽  
Vol 30 (05) ◽  
pp. 395-400
Author(s):  
Annika Mutanen ◽  
Mikko P. Pakarinen

AbstractThe incidence of Crohn's disease is increasing worldwide. The clinical course of childhood onset Crohn's disease is particularly aggressive with characteristic disease localization in the ileocecal region and colon, often associated with perianal disease. Severe complications of perianal disease include recurrent perianal sepsis, chronic fistulae, fecal incontinence, and rectal strictures that impair quality of life and may require fecal diversion. Care of patients with perianal Crohn's disease requires a multidisciplinary approach with systematic clinical evaluation, endoscopic assessment, and imaging studies followed by combined medical and surgical management. In this review, we provide an update of the epidemiology, pathophysiology, diagnostics, and management of perianal Crohn's disease in children and adolescents.


2013 ◽  
Vol 7 ◽  
pp. S101
Author(s):  
M. Barreiro-de Acosta ◽  
M. Iglesias-Rey ◽  
A. Lorenzo ◽  
J.E. Dominguez-Munoz

2019 ◽  
Vol 50 (11-12) ◽  
pp. 1195-1203
Author(s):  
Joyce Wing Yan Mak ◽  
Whitney Tang ◽  
Terry Cheuk Fung Yip ◽  
Zhi Hua Ran ◽  
Shu Chen Wei ◽  
...  

2010 ◽  
Vol 192 (7) ◽  
pp. 375-377 ◽  
Author(s):  
Daniel C Burger ◽  
Ian C Lawrance ◽  
Peter A Bampton ◽  
Ruth Prosser ◽  
Anthony Croft ◽  
...  

2000 ◽  
Vol 14 (suppl c) ◽  
pp. 7C-12C ◽  
Author(s):  
Paul Rutgeerts

Perianal inflammation is a disabling manifestation of Crohn’s disease. The primary lesions found in perianal Crohn’s disease evolve in parallel with the disease elsewhere in the bowel. Although the spontaneous resolution of anal lesions is observed in up to half of patients, the penetrating nature of the disease may lead to secondary lesions including complex fistulae. In some patients, this, in turn, results in the gradual destruction of the sphincter apparatus and anal incontinence. These patients, after years of suffering, often require proctectomy. Control of activity, overall, is the first step in the management of perianal Crohn’s disease. Sepsis should be controlled by the drainage of abscesses and by long term use of setons. Although antibiotics and standard immunosuppression often improve perianal fistulae, their action is usually slow and incomplete. Management of perianal Crohn’s disease has changed thoroughly in the past two years since the introduction of monoclonal antibodies to tumour necrosis factor (infliximab). Complete arrest of the drainage of fistulae was obtained in 46% of patients after the administration of 5 to 10 mg/kg of infliximab at weeks 0, 2 and 6, with a median duration of effect of 12 weeks. In these patients, long term management of their bowel disease will likely require the repeated use of infliximab. Studies to evaluate this are underway.


2012 ◽  
Vol 13 (10) ◽  
pp. 1287-1293 ◽  
Author(s):  
Antonino Spinelli ◽  
Chiara De Cassan ◽  
Matteo Sacchi ◽  
Piero Bazzi ◽  
Silvio Danese ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document